Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Here, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas Disease.

Silva-Neto MA, Lopes AH, Atella GC.

Front Immunol. 2016 Feb 19;7:62. doi: 10.3389/fimmu.2016.00062. eCollection 2016. Review.

2.

Genetic Susceptibility to Cardiac and Digestive Clinical Forms of Chronic Chagas Disease: Involvement of the CCR5 59029 A/G Polymorphism.

de Oliveira AP, Bernardo CR, Camargo AV, Ronchi LS, Borim AA, de Mattos CC, de Campos Júnior E, Castiglioni L, Netinho JG, Cavasini CE, Bestetti RB, de Mattos LC.

PLoS One. 2015 Nov 23;10(11):e0141847. doi: 10.1371/journal.pone.0141847. eCollection 2015.

3.

Kinases as druggable targets in trypanosomatid protozoan parasites.

Merritt C, Silva LE, Tanner AL, Stuart K, Pollastri MP.

Chem Rev. 2014 Nov 26;114(22):11280-304. doi: 10.1021/cr500197d. Epub 2014 Oct 7. Review. No abstract available.

4.

Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.

Penitente AR, Leite AL, de Paula Costa G, Shrestha D, Horta AL, Natali AJ, Neves CA, Talvani A.

Am J Trop Med Hyg. 2015 Nov;93(5):976-82. doi: 10.4269/ajtmh.15-0237. Epub 2015 Sep 8.

PMID:
26350447
5.

Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of Trypanosoma cruzi.

Santos EC, Novaes RD, Cupertino MC, Bastos DS, Klein RC, Silva EA, Fietto JL, Talvani A, Bahia MT, Oliveira LL.

Antimicrob Agents Chemother. 2015 Oct;59(10):5999-6006. doi: 10.1128/AAC.00779-15. Epub 2015 Jul 13.

6.

Human leucocyte antigen-G (HLA-G) and its murine functional homolog Qa2 in the Trypanosoma cruzi Infection.

Dias FC, Mendes-Junior CT, Silva MC, Tristão FS, Dellalibera-Joviliano R, Moreau P, Soares EG, Menezes JG, Schmidt A, Dantas RO, Marin-Neto JA, Silva JS, Donadi EA.

Mediators Inflamm. 2015;2015:595829. doi: 10.1155/2015/595829. Epub 2015 Jan 20.

7.

The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs.

Duz AL, Vieira PM, Roatt BM, Aguiar-Soares RD, Cardoso JM, Oliveira FC, Reis LE, Tafuri WL, Veloso VM, Reis AB, Carneiro CM.

Mem Inst Oswaldo Cruz. 2014 Dec;109(8):1005-13. doi: 10.1590/0074-02760140208.

8.

Early double-negative thymocyte export in Trypanosoma cruzi infection is restricted by sphingosine receptors and associated with human chagas disease.

Lepletier A, de Almeida L, Santos L, da Silva Sampaio L, Paredes B, González FB, Freire-de-Lima CG, Beloscar J, Bottasso O, Einicker-Lamas M, Pérez AR, Savino W, Morrot A.

PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3203. doi: 10.1371/journal.pntd.0003203. eCollection 2014 Oct.

9.

Trypanosoma cruzi infection and host lipid metabolism.

Miao Q, Ndao M.

Mediators Inflamm. 2014;2014:902038. doi: 10.1155/2014/902038. Epub 2014 Sep 3. Review.

10.

Mouse macrophage galactose-type lectin (mMGL) is critical for host resistance against Trypanosoma cruzi infection.

Vázquez A, Ruiz-Rosado Jde D, Terrazas LI, Juárez I, Gomez-Garcia L, Calleja E, Camacho G, Chávez A, Romero M, Rodriguez T, Espinoza B, Rodriguez-Sosa M.

Int J Biol Sci. 2014 Aug 23;10(8):909-20. doi: 10.7150/ijbs.9214. eCollection 2014.

11.

The acute phase of Trypanosoma cruzi infection is attenuated in 5-lipoxygenase-deficient mice.

Canavaci AM, Sorgi CA, Martins VP, Morais FR, de Sousa ÉV, Trindade BC, Cunha FQ, Rossi MA, Aronoff DM, Faccioli LH, Nomizo A.

Mediators Inflamm. 2014;2014:893634. doi: 10.1155/2014/893634. Epub 2014 Aug 3.

12.

Chagas disease in the 21st century: a public health success or an emerging threat?

Bonney KM.

Parasite. 2014;21:11. doi: 10.1051/parasite/2014012. Epub 2014 Mar 10. Review.

13.

Modulation of immune response in experimental Chagas disease.

Basso B.

World J Exp Med. 2013 Feb 20;3(1):1-10. doi: 10.5493/wjem.v3.i1.1. eCollection 2013 Feb 20. Review.

14.

Polymorphic sites at the immunoregulatory CTLA-4 gene are associated with chronic chagas disease and its clinical manifestations.

Dias FC, Medina Tda S, Mendes-Junior CT, Dantas RO, Pissetti CW, Rodrigues Junior V, Dellalibera-Joviliano R, Marin-Neto JA, Gutierrez FR, Moreau P, Silva JS, Donadi EA.

PLoS One. 2013 Oct 24;8(10):e78367. doi: 10.1371/journal.pone.0078367. eCollection 2013.

15.

In vitro and in vivo studies of the trypanocidal activity of four terpenoid derivatives against Trypanosoma cruzi.

Ramírez-Macías I, Marín C, Chahboun R, Messouri I, Olmo F, Rosales MJ, Gutierrez-Sánchez R, Alvarez-Manzaneda E, Sánchez-Moreno M.

Am J Trop Med Hyg. 2012 Sep;87(3):481-8. doi: 10.4269/ajtmh.2012.11-0471. Epub 2012 Jul 16.

16.

Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens.

Sathler-Avelar R, Vitelli-Avelar DM, Elói-Santos SM, Gontijo ED, Teixeira-Carvalho A, Martins-Filho OA.

BMC Infect Dis. 2012 May 24;12:123. doi: 10.1186/1471-2334-12-123.

17.

IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils.

Tosello Boari J, Amezcua Vesely MC, Bermejo DA, Ramello MC, Montes CL, Cejas H, Gruppi A, Acosta Rodríguez EV.

PLoS Pathog. 2012;8(4):e1002658. doi: 10.1371/journal.ppat.1002658. Epub 2012 Apr 26.

18.

IFN-γ plays a unique role in protection against low virulent Trypanosoma cruzi strain.

Rodrigues AA, Saosa JS, da Silva GK, Martins FA, da Silva AA, Souza Neto CP, Horta CV, Zamboni DS, da Silva JS, Ferro EA, da Silva CV.

PLoS Negl Trop Dis. 2012;6(4):e1598. doi: 10.1371/journal.pntd.0001598. Epub 2012 Apr 3.

19.

Different infective forms trigger distinct immune response in experimental Chagas disease.

Vieira PM, Francisco AF, Machado EM, Nogueira NC, Fonseca Kda S, Reis AB, Teixeira-Carvalho A, Martins-Filho OA, Tafuri WL, Carneiro CM.

PLoS One. 2012;7(3):e32912. doi: 10.1371/journal.pone.0032912. Epub 2012 Mar 7.

20.

Pathogenesis of Chagas disease: time to move on.

Machado FS, Tyler KM, Brant F, Esper L, Teixeira MM, Tanowitz HB.

Front Biosci (Elite Ed). 2012 Jan 1;4:1743-58.

Items per page

Supplemental Content

Write to the Help Desk